+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

This prospective observational study focuses on patients who experience out-of-hospital cardiac arrest OHCA. The study aims to monitor core body temperature using an esophageal probe during transport and upon arrival at the hospital. Researchers also observe environmental factors like ambient temperature and interventions used to prevent hypothermia during resuscitation based on European Resuscitation Council Guidelines 2015 or newer. When a patient meets inclusion criteria and CPR is established according to guidelines, an esophageal temperature probe is inserted on site during ongoing resuscitation efforts. Body temperature is measured on scene and again upon hospital arrival using the probe. Data on weather conditions, altitude, patient activity, and hypothermia protection such as clothing are also recorded throughout the process. Participants are monitored from the moment resuscitation begins until hospital arrival, with core temperature measured continuously. Additional data collected include environmental temperature at the site, time from cardiac arrest to return of spontaneous circulation ROSC, heart rhythm at arrival of advanced life support teams, and use of mechanical chest compression devices. The primary outcome is core temperature at hospital arrival, tracked over an average of one year during study completion.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

This research aims to evaluate whether acral cryotherapy can reduce the incidence and severity of chemotherapy-induced peripheral neuropathy CIPN in female breast cancer patients receiving weekly paclitaxel-based chemotherapy. CIPN is a common side effect caused by nerve damage during chemotherapy, which can affect quality of life and lead to treatment changes or stopping treatment. The study compares patients receiving cryotherapy with those receiving standard care without cryotherapy. Participants in the cryotherapy group will use the Hilotherm Chemocare device that delivers continuous-flow cold at 15C to the hands and feet. This cooling starts 15 minutes before chemotherapy infusion, continues during the infusion, and lasts 15 minutes after. The control group will receive standard care without cryotherapy. The study involves randomized assignment to either group. During chemotherapy and for one year after completing treatment, participants will undergo repeated assessments including neurological exams, nerve conduction studies, patient questionnaires on quality of life, and blood tests. Additional blood samples will be collected at two time points to analyze biomarkers of nerve damage. The main outcome measured is the change in neuropathy score from before treatment to six months after chemotherapy ends.

Age: 18Years - 90YearsFEMALEPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are evaluating treatment strategies for patients diagnosed with Rheumatoid Arthritis RA who have moderate or high disease activity despite ongoing conventional or biologic therapies. The study aims to compare a standard clinical decision approach with a combined clinical and ultrasound-guided treatment decision to see which better achieves low disease activity or remission by week 24. This randomized, multicenter clinical trial intends to assess whether using ultrasound can improve treatment outcomes in RA. Participants are randomly assigned to one of two groups the control group receives a new course of biologic or targeted synthetic DMARDs with or without conventional DMARDs, with therapy adjustments based on clinical assessment at 12 weeks. The experimental group receives similar treatment but with additional ultrasound evaluations of 44 joints at baseline, 12, 24, and 48 weeks to guide treatment decisions. If inflammation is detected by both clinical and ultrasound assessment, treatment is adjusted accordingly otherwise, pain management is stepped up while background therapy continues. During the 48-week active phase, participants undergo multiple assessments including clinical disease activity scores, ultrasound imaging, and various patient-reported outcomes such as pain scales, fatigue, and quality of life questionnaires. Laboratory tests like ESR and CRP are also monitored. The study tracks changes in joint counts, remission rates, and physical function at regular intervals, with primary outcomes evaluated at week 24. Safety and treatment efficacy are closely monitored throughout, with total study duration planned for up to 72 months including recruitment and follow-up.

Age: 18Years - 84YearsAll GendersPhase Not Applicable
1 location